{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T13:59:26Z","timestamp":1648994366271},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull Exp Biol Med"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s10517-017-3859-y","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T04:38:12Z","timestamp":1506314292000},"page":"605-607","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Activities of Proline-Specific Proteinases in the Serum and Cerebrospinal Fluid of Rats with the Fetal Valproate Syndrome"],"prefix":"10.1007","volume":"163","author":[{"given":"E. A.","family":"Ivanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. G.","family":"Kapitsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. N.","family":"Zolotov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. F.","family":"Pozdnev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. A.","family":"Voronina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"issue":"1","key":"3859_CR1","first-page":"234","volume":"317","author":"NN Zolotov","year":"1991","unstructured":"Zolotov NN, Kutenova NN, Voronina NN, Pozdnev NN, Smirnov LD, Diumaev KM. The possible participation of brain peptidases in regulating the memory function during aging. Dokl. Akad. Nauk SSSR. 1991;317(1):234-237. Russian.","journal-title":"Dokl. Akad. Nauk SSSR."},{"issue":"5","key":"3859_CR2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s10517-013-2010-y","volume":"154","author":"NA Krupina","year":"2013","unstructured":"Krupina NA, Bogdanova NG, Khlebnikova NN, Zolotov NN, Kryzhanovskii GN. Benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine, a prolyl endopeptidase inhibitor, modulates depression-like behavior of rats in forced swimming test and activities of proline-specific peptidases in the brain structures. Bull. Exp. Biol. Med. 2013;154(5):606-609.","journal-title":"Bull. Exp. Biol. Med."},{"key":"3859_CR3","first-page":"29","volume":"3","author":"OY Sokolov","year":"2010","unstructured":"Sokolov OYu, Kost NV, Andreeva OO, Korneeva EV, Meshavkin VK, Tarakanova YuN, Dadayan AK, Zolotarev YuA, Grachev SA, Mikheeva IG, Zozulya AA. Possible role of casomorphins in the pathogenesis of autism. Psikhiatriya. 2010;(3): 29-35. Russian.","journal-title":"Psikhiatriya."},{"issue":"6","key":"3859_CR4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10517-013-2233-y","volume":"155","author":"NN Khlebnikova","year":"2013","unstructured":"Khlebnikova NN, Krupina NA, Bogdanova NG, Zolotov NN. Effect of prolyl endopeptidase inhibitor benzyloxycarbonylmethionyl-2(S)-cyanopyrrolidine on activity of proline-specific peptidases in brain structures of rats with experimental MPTP-induced depressive syndrome. Bull. Exp. Biol. Med. 2013;155(6):711-714.","journal-title":"Bull. Exp. Biol. Med."},{"issue":"1","key":"3859_CR5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1469-7610.1996.tb01381.x","volume":"37","author":"A Bailey","year":"1996","unstructured":"Bailey A, Phillips W, Rutter M. Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. J. Child Psychol. Psychiatry. 1996;37(1):89-126.","journal-title":"J. Child Psychol. Psychiatry."},{"issue":"2","key":"3859_CR6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.npbr.2014.03.001","volume":"20","author":"S Bashir","year":"2014","unstructured":"Bashir S, AL-Ayadhi L. Alterations in plasma dipeptidyl peptidase IV in autism: A pilot study. Neurol. Psychiatry Brain Res. 2014;20(2):41-44.","journal-title":"Neurol. Psychiatry Brain Res."},{"issue":"5","key":"3859_CR7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1054\/mehy.2001.1513","volume":"58","author":"MA Brudnak","year":"2002","unstructured":"Brudnak MA, Rimland B, Kerry RE, Dailey M, Taylor R, Stayton B, Waickman F, Waickman M, Pangborn J, Buchholz I. Enzyme-based therapy for autism spectrum disorders \u2014 is it worth another look? Med. Hypotheses 2002, Vol. 58(5):422-428.","journal-title":"Med. Hypotheses"},{"key":"3859_CR8","doi-asserted-by":"crossref","unstructured":"Chomiak T, Turner N, Hu B. What we have learned about autism spectrum disorder from valproic acid. Patholog. Res. Int. 2013;2013. ID 712758. doi: 10.1155\/2013\/712758.","DOI":"10.1155\/2013\/712758"},{"issue":"2","key":"3859_CR9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1212\/WNL.57.2.245","volume":"57","author":"E Courchesne","year":"2001","unstructured":"Courchesne E, Karns C. M, Davis HR, Ziccardi R, Carper RA, Tigue ZD, Chisum HJ, Moses P, Pierce K, Lord C, Lincoln AJ, Pizzo S, Schreibman L, Haas RH, Akshoomoff NA, Courchesne RY. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology 2001;57(2):245-254.","journal-title":"Neurology"},{"key":"3859_CR10","doi-asserted-by":"crossref","unstructured":"Gottfried C, Bambini-Junior V, Baronio D, Zanatta G, Bristot Silvestrin R, Vaccaro T, Riesgo R. Valproic acid in autisms disorder: from an environmental risk factor to a reliable animal model. Recent Advances in Autism Spectrum Disorders. Fitzgerald M, ed. InTech, 2013 Vol. 1, Ch. 8. P. 143-163. doi: 10.5772\/54824.","DOI":"10.5772\/54824"},{"issue":"12","key":"3859_CR11","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/archpsyc.62.12.1366","volume":"62","author":"HC Hazlett","year":"2005","unstructured":"Hazlett HC, Poe M, Gerig G, Smith RG, Provenzale J, Ross A, Gilmore J, Piven J. Magnetic resonance imaging and head circumference study of brain size in autism: birth through age 2 years. Arch. Gen. Psychiatry. 2005;62(12):1366-1376.","journal-title":"Arch. Gen. Psychiatry."},{"issue":"3","key":"3859_CR12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0165-1781(95)02698-V","volume":"58","author":"M Maes","year":"1995","unstructured":"Maes M, Goossens F, Scharpe S, Calabrese J, Desnyder R, Meltzer HY. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res. 1995;58(3):217-225.","journal-title":"Psychiatry Res."},{"issue":"1","key":"3859_CR13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1742-7843.2010.00626.x","volume":"108","author":"I Peltonen","year":"2010","unstructured":"Peltonen I, M\u00e4nnist\u00f6 PT. Effects of diverse psychopharmacological substances on the activity of brain prolyl oligopeptidase. Basic Clin. Pharmacol. Toxicol. 2010;108(1):46-54.","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"12","key":"3859_CR14","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1523\/JNEUROSCI.5714-09.2010","volume":"30","author":"CM Schumann","year":"2010","unstructured":"Schumann CM, Bloss CS, Barnes CC, Wideman GM, Carper RA, Akshoomoff N, Pierce K, Hagler D, Schork N, Lord C, Courchesne E. Longitudinal magnetic resonance imaging study of cortical development through early childhood in autism. J. Neurosci. 2010;30(12):4419-4427.","journal-title":"J. Neurosci."},{"issue":"2","key":"3859_CR15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/14728222.6.2.175","volume":"6","author":"P Shattock","year":"2002","unstructured":"Shattock P, Whiteley P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin. Ther. Targets. 2002;6(2):175-183.","journal-title":"Expert Opin. Ther. Targets."}],"container-title":["Bulletin of Experimental Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10517-017-3859-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10517-017-3859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10517-017-3859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T22:57:09Z","timestamp":1507244229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10517-017-3859-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["3859"],"URL":"https:\/\/doi.org\/10.1007\/s10517-017-3859-y","relation":{},"ISSN":["0007-4888","1573-8221"],"issn-type":[{"value":"0007-4888","type":"print"},{"value":"1573-8221","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}